Breast implant adverse events: what 347,618 FDA MAUDE reports reveal

Breast augmentation has been the most common surgical cosmetic procedure in the United States for most of the past decade. ASPS procedural statistics recorded 306,196 breast augmentations in 2024, alongside 41,271 implant removals among augmentation patients — a figure that has held essentially flat year over year even as explant awareness has grown. Whether placed for cosmetic enlargement or post-mastectomy reconstruction, breast implants are regulated as Class III medical devices — the FDA's highest-risk device category, requiring Premarket Approval (PMA) applications backed by clinical data before they can be sold.

That Class III designation matters for where the safety data lives. Implant adverse events flow into the FDA's MAUDE database (Manufacturer and User Facility Device Experience), the passive-surveillance system that aggregates mandatory manufacturer reports, mandatory facility reports, and voluntary reports from patients and clinicians. MAUDE is well known to underreport, so the cases that surface are a fraction of real-world events — but for the most widely implanted aesthetic device ever sold, the database is the closest thing to a public postmarket safety ledger that exists.

An analysis of 347,618 adverse event reports under FDA product codes FTR ("Prosthesis, Breast, Silicone Gel-Filled") and FWM ("Prosthesis, Breast, Saline-Filled") — received between 1984 and May 2026 — shows which complications, which manufacturers, and which time periods dominate the safety record behind the most common aesthetic implant.

The dataset at a glance

Nearly every report (97%) describes a patient injury rather than a manufacturing defect. The 242 death reports are discussed below; MAUDE records that a death occurred in association with a device, which is not the same as proving the implant caused it. The raw count is also not a rate: breast implants are a high-volume, decades-long exposure, so absolute report counts are large even at low per-implant rates.

When the reports arrived

The reporting volume is not steady. It rose sharply in the late 2010s and has stayed elevated since.

Reports jumped roughly sevenfold between 2017 and 2019 and have held near 40,000 per year ever since. Two events drove the surge. First, in July 2019, the FDA requested that Allergan voluntarily recall its BIOCELL textured breast implants and tissue expanders worldwide over the rare cancer breast implant-associated anaplastic large cell lymphoma (BIA-ALCL); that recall and the publicity around it prompted a wave of reporting and explant activity. Second, in September 2020, the FDA published its first analysis of medical device reports describing systemic symptoms in women with implants — the cluster patients call "breast implant illness" (BII) — which further raised reporting volume and public awareness. The FDA strengthened breast implant labeling again in October 2021 (below).

Which manufacturers show up most

Grouping the reports that name a specific implant line shows how concentrated the implant market is, and how thoroughly Allergan dominates the safety record.

Allergan's products appear in the majority of brand-named reports — consistent with both its large U.S. market share and the fact that the recalled BIOCELL textured line was an Allergan product. These shares are not direct risk rates. They reflect market exposure and reporting intensity: the most-implanted brands generate the most reports even at low per-device rates. A manufacturer that appears at the top of this table is not necessarily riskier per implant — it is more used and, in Allergan's case, was the subject of a high-profile recall that concentrated reporting.

The dominant complications: rupture and capsular contracture

Scanning the narrative text across the FTR and FWM records, two mechanical complications dominate the safety record by a wide margin.

Rupture and capsular contracture — hardening of the scar-tissue capsule that forms around every implant — account for the bulk of serious reports. The FDA cites capsular contracture rates as high as 28% over the lifetime of an implant; published long-term studies place problematic contracture in a roughly 2.5–19% range. Severity is graded on the four-point Baker scale (I–IV), with grades III–IV — visible distortion, firmness, and often pain — typically driving revision. The two fill types present differently when they fail. Saline implants (FWM) deflate visibly when the shell fails: the breast changes size over hours to days as saline is absorbed. Silicone gel implants (FTR) can fail "silently," with gel remaining in the capsule; the FDA recommends MRI or ultrasound screening for silent rupture starting five to six years after placement and every two to three years thereafter. Reported rupture rates vary widely — roughly 1–35% within a decade depending on implant generation and screening method — and published estimates rise to roughly 35–50% around the 20-year mark; counting all complications, about half of implants have failed by 15 years in some series. Leak and deflation largely track rupture across the two fill types.

These are also the complications that drive reoperation. The FDA's patient materials state plainly that breast implants are not lifetime devices, that the chance of complications increases over time, and that some complications require more surgery — a point the agency reinforced when it ordered a boxed warning on all breast implants in 2021.

BIA-ALCL: the cancer that drove the Allergan recall

The most consequential safety finding in the breast-implant record is a rare T-cell lymphoma linked overwhelmingly to textured-surface implants.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a cancer of the immune system, not a breast cancer. The FDA first flagged a possible association in 2011. As of the FDA's running tally, 1,380 unique BIA-ALCL cases had been reported to the agency in medical device reports since then. The American Society of Plastic Surgeons, as of May 30, 2025, recognized approximately 458 suspected or confirmed cases in the United States and 1,618 worldwide. The disease usually presents years after implantation as a delayed seroma (fluid), a mass, or persistent swelling around the implant.

BIA-ALCL is overwhelmingly a disease of textured implants. At the time of the recall, the FDA found that roughly 84% of cases with a known manufacturer — 481 of 573 — occurred in people who had received Allergan BIOCELL textured implants, and that the BIA-ALCL risk with BIOCELL implants was roughly six times the risk of textured implants from other U.S. manufacturers. On July 24, 2019, the FDA requested a recall; Allergan agreed to a worldwide recall of BIOCELL textured implants and tissue expanders. Of 33 deaths recorded in association with BIA-ALCL at the time of the recall, the implant manufacturer could be identified in 13, and 12 of those involved Allergan.

The MAUDE data shows the recall landing in the reporting record. Mentions of ALCL or anaplastic large cell lymphoma in FTR/FWM reports jumped from 234 in 2018 to 798 in 2019, then held in the hundreds per year (359–736) through 2025. The 5,107 FTR/FWM records that mention ALCL or anaplastic are report records, not unique cases — they include duplicates and reports that reference the disease — so they cannot be read as a case count. The authoritative case count is the FDA's curated tally above.

Textured implants are a minority of the market — textured shells account for roughly 10% of breast implants, and the macro-textured BIOCELL designs that were recalled were a subset of those — yet they account for the overwhelming majority of a rare but serious cancer. Among MAUDE reports that specify surface texture in the brand name, 27,494 name a textured implant and 71,811 a smooth one; the majority of reports do not specify texture at all.

Breast implant illness (BII): real symptoms, contested mechanism

A second cluster sits alongside BIA-ALCL in the record: systemic symptoms patients attribute to their implants. "Breast implant illness" (BII) describes fatigue, brain fog, joint and muscle pain, hair loss, rashes, anxiety, and similar complaints reported with all types of implants — silicone and saline, smooth and textured.

The FDA's analysis of the systemic-symptom MDRs lists the most commonly reported signs:

In the FTR/FWM dataset, 2,759 records mention "breast implant illness" and 676 the shorthand "BII." The FDA is explicit that BII's causes are poorly understood and that it has not detected an association between silicone gel implants and connective-tissue disease. At the same time, the agency acknowledges that some patients report their symptoms resolve after the implants are removed without replacement. The honest framing is that the symptoms are real and well-documented in reports, the mechanism is not settled, and explant appears to help some patients.

The 242 death reports

Death is the most sensitive number in the dataset, and it requires the most care. The 242 death-flagged records indicate that a death occurred and was reported in association with an FTR or FWM device. MAUDE's standard is association, not causation — a report may describe a death from advanced BIA-ALCL, from a surgical complication of explant or replacement, from a cause unrelated to the implant, or from an event where the implant's role cannot be determined. BIA-ALCL itself is "rarely fatal" when caught early and treated surgically, but it can be lethal if it progresses.

The defensible reading is that deaths have occurred in temporal and clinical association with breast implants, and that BIA-ALCL has caused some of them — not that 242 deaths were caused by implants. Any precise mortality count belongs to the FDA's curated analyses, not to a raw MAUDE query.

What the FDA changed in 2021

On October 27, 2021, the FDA overhauled breast implant risk communication. The agency ordered that all breast implants sold in the U.S. carry:

• a boxed (black-box) warning stating that implants are not lifetime devices, that complication risk rises over time, that some complications require surgery, and that implants are associated with BIA-ALCL and with systemic symptoms (BII);
• a Patient Decision Checklist that must be reviewed and signed by both patient and implanter;
• a Patient Device Card recording the specific implant model, lot, and serial number; and
• updated rupture-screening recommendations (MRI or ultrasound).

The FDA also restricted the sale and distribution of implants to providers and facilities that provide the manufacturer's patient brochure and checklist. If you have implants and do not know what kind, the Patient Device Card or your operative report should say; if it does not, the implanting surgeon or facility can look it up.

What MAUDE cannot tell you

MAUDE is a passive system. Reporting is incomplete, biased toward severe and recent events, and concentrated around recalls and media coverage. The 347,618 reports here are a fraction of actual events, and the injury-type counts are mentions in free text, not coded diagnoses. The dataset is most reliable for patterns — which complications, which manufacturers, which years — and not for precise incidence or risk rates. True risk rates come from the FDA's curated analyses, the manufacturers' post-approval studies, and population-level epidemiology, not from a raw MAUDE count.

What to ask before breast implant surgery

• Which implant, and what surface? Smooth vs. textured matters: BIA-ALCL is overwhelmingly a textured-implant disease, and the recalled Allergan BIOCELL textured implants carried roughly six times the BIA-ALCL risk of other textured lines.
• Have you received and signed the Patient Decision Checklist? Since November 2021, FDA rules require it. If you were not offered one, ask why.
• What is the rupture-surveillance plan? For silicone implants, this means MRI or ultrasound starting around five to six years and every two to three years after. Ask how silent rupture would be detected.
• What is the reoperation rate in your surgeon's own patients? Capsular contracture, rupture, and asymmetry are the common reasons implants come back to the operating room over a lifetime.
• What symptoms would prompt evaluation? Late persistent swelling, a mass, or a new seroma years after augmentation should prompt evaluation for BIA-ALCL. Systemic symptoms compatible with BII are worth discussing with the implanter or a clinician familiar with implant-related illness.

Patients with implants who develop persistent swelling, a lump, or pain years after placement should be evaluated — these are the typical presentations of BIA-ALCL, and early surgical treatment is usually curative. Adverse events can be reported to the FDA through the MedWatch system.

Sources

• FDA — Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-breast-implant-associated-anaplastic-large-cell-lymphoma
• FDA — Medical Device Reports for Systemic Symptoms in Women with Breast Implants (BII): https://www.fda.gov/medical-devices/breast-implants/medical-device-reports-systemic-symptoms-women-breast-implants
• FDA — Risks and Complications of Breast Implants: https://www.fda.gov/medical-devices/breast-implants/risks-and-complications-breast-implants
• FDA press release — FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall (July 24, 2019): https://www.fda.gov/news-events/press-announcements/fda-takes-action-protect-patients-risk-certain-textured-breast-implants-requests-allergan
• FDA — Allergan Voluntarily Recalls BIOCELL Textured Breast Implants and Tissue Expanders: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/allergan-voluntarily-recalls-biocellr-textured-breast-implants-and-tissue-expanders
• FDA — FDA Strengthens Breast Implant Safety Requirements (October 27, 2021): https://www.fda.gov/news-events/press-announcements/fda-strengthens-breast-implant-safety-requirements
• American Society of Plastic Surgeons — BIA-ALCL Physician Resources (458 US cases, 1,618 worldwide as of May 30, 2025): https://www.plasticsurgery.org/for-medical-professionals/health-policy/bia-alcl-physician-resources
• American Society of Plastic Surgeons — Breast Implant Safety: https://www.plasticsurgery.org/patient-safety/breast-implant-safety
• American Society of Plastic Surgeons — 2024 Plastic Surgery Statistics Report (306,196 augmentations; 41,271 implant removals among augmentation patients, 2024): https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf
• American Society of Plastic Surgeons — What you need to know about capsular contracture (FDA lifetime rate up to 28%; Baker grading): https://www.plasticsurgery.org/news/articles/heres-what-you-need-to-know-about-capsular-contracture
• Cleveland Clinic — BIA-ALCL: Breast Implant-Associated Cancer, Symptoms & Treatment: https://my.clevelandclinic.org/health/diseases/21078-bia-alcl
• Mazzarello V, et al. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: A Review. Yonsei Med J. (review of FDA MDR data): https://www.e-jyms.org/upload/pdf/yujm-2020-00801.pdf

Analysis sample: FDA MAUDE database extract dated 2026-06-10, 347,618 adverse event reports under product codes FTR (Prosthesis, Breast, Silicone Gel-Filled) and FWM (Prosthesis, Breast, Saline-Filled), received 1984 through May 2026. Complication counts are narrative-text mentions across the device-coded subset and include duplicates; they are not coded diagnoses or incidence rates. Manufacturer and texture groupings assigned from the brand_name field. Analysis by AestheticMedGuide.